ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
To determine if therapy with Zometa® (zoledronic acid) 4mg will be effective in preventing
the occurrence of bone metastases in prostate cancer patients at high risk of developing
them. In addition, pain and analgesic scores and overall safety are to be evaluated
throughout the study.